CA2677822A1 — Antihypertensive drug combination
Assigned to Gilead Colorado Inc · Expires 2008-08-21 · 18y expired
What this patent protects
Therapeutic combinations and pharmaceutical compositions are provided comprising darusentan and an inhibitor of renin activity or release in absolute and relative amounts effective to provide a beneficial change in a subject's 24-hour pattern of systolic and/or diastolic blood pr…
USPTO Abstract
Therapeutic combinations and pharmaceutical compositions are provided comprising darusentan and an inhibitor of renin activity or release in absolute and relative amounts effective to provide a beneficial change in a subject's 24-hour pattern of systolic and/or diastolic blood pressure. There are further provided methods of using such combinations or compositions to treat hypertensive disorders, or to lower blood pressure in subjects exhibiting resistance to a baseline antihypertensive therapy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.